The tumor-initiating role of CSNK1D is further supported by our findings that pharmacological inhibition of CSNK1D abrogates the tumor initiation and in vivo engraftment capacity of GLI-dependent PANC1 cells [60]. The gene discussed is CSNK1D; the disease is neoplasm.